Regencell Bioscience Holdings Ltd - Understand $rgc stock

$RGC Market Cap: $70.79 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$7.446M

TTM

Current Assets

$8.114M

Q2 2024

Current Liabilities

$193.6K

Q2 2024

Current Ratio

4191.6%

Q2 2024

Total Assets

$8.438M

Q2 2024

Total Liabilities

$219.5K

Q2 2024

Book Value

$8.219M

Q2 2024

Cash

$2.961M

Q2 2024

P/E

-9.507

Nov 29, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019
Revenue		$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019
Selling, General & Admin	$3.670M	$4.692M	$5.106M	$943.0K	$426.1K	$162.8K
YoY Change	-21.77%	-8.1%	441.4%	121.3%	161.81%
% of Gross Profit
Research & Development	$1.066M	$1.582M	$2.512M	$438.3K	$386.2K	$228.2K
YoY Change	-32.59%	-37.04%	473.13%	13.49%	69.24%
% of Gross Profit
Depreciation & Amortization	$305.8K	$293.1K	$150.1K	$26.46K	$9.520K	$0.00
YoY Change	4.31%	95.23%	467.45%	177.94%
% of Gross Profit
Operating Expenses	$4.737M	$6.274M	$7.618M	$1.381M	$812.4K	$391.0K
YoY Change	-24.5%	-17.64%	451.47%	70.04%	107.77%
Operating Profit	-$4.737M	-$6.274M	-$7.618M	-$1.381M	-$812.4K
YoY Change	-24.5%	-17.64%	451.47%	70.04%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$210.0K	$23.22K	$34.62K
YoY Change	804.39%	-32.93%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019
Pretax Income	-$4.363M	-$6.062M	-$7.595M	-$1.347M	-$812.4K	-$391.0K
YoY Change	-28.03%	-20.18%	463.92%	65.78%	107.77%
Income Tax				$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.302M	-$5.871M	-$7.595M	-$1.347M	-$812.4K	-$391.0K
YoY Change	-26.73%	-22.69%	463.92%	65.78%	107.77%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.33	$0.45	$0.58	$0.13	$0.08
Diluted Earnings Per Share	-$0.33	-$0.45	-$0.58	-$106.5K	-$64.26K	-$30.93K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019
Cash & Short-Term Investments	$11.56M	$16.42M	$59.41K	$387.0K	$243.3K
YoY Change	-29.59%	27533.4%	-84.65%	59.05%
Cash & Equivalents
Short-Term Investments	$10.00M	$10.00M
Other Short-Term Assets	$60.00K	$27.60K	$7.440K
YoY Change	117.39%	270.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$11.62M	$16.44M	$66.85K	$387.0K	$243.3K
YoY Change	-29.34%	24499.25%	-82.73%	59.05%
Property, Plant & Equipment	$890.0K	$1.460M	$81.87K	$108.3K	$0.00
YoY Change	-39.04%	1683.34%	-24.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$110.0K	$114.3K	$191.4K	$18.72K	$0.00
YoY Change	-3.76%	-40.29%	922.54%
Total Long-Term Assets	$1.000M	$1.574M	$273.3K	$127.0K	$0.00
YoY Change	-36.48%	476.08%	115.11%
Total Assets	$12.62M	$18.02M	$340.1K	$514.0K	$243.3K
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$600.0K	$562.1K	$573.0K	$95.00K	$0.00
YoY Change	6.74%	-1.9%	503.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$432.0K	$3.070M	$2.082M
YoY Change		-100.0%	-85.93%	47.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$610.0K	$577.8K	$4.338M	$3.165M	$2.082M
YoY Change	5.58%	-86.68%	37.06%	52.03%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K	$360.3K
YoY Change	-91.67%
Total Long-Term Liabilities	$30.00K	$360.3K	$0.00	$0.00	$0.00
YoY Change	-91.67%
Total Liabilities	$590.0K	$953.4K	$4.338M	$3.165M	$2.082M
YoY Change	-38.12%	-78.02%	37.06%	52.03%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2021	2020
Basic Shares Outstanding	13.01M shares	13.01M shares	12.81M shares	10.00M shares	10.00M shares
Diluted Shares Outstanding	13.01M shares	13.01M shares	12.81M shares	10.00M shares	10.00M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $70.79 Million

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Industry: Medicinal Chemicals & Botanical Products Peers: